Comparing Fortress Biotech


Fortress Biotech and Syros Pharmaceuticals are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Fortress Biotech presently has a consensus price target of $11.00, suggesting a potential upside of 172.95%.



from Biotech News